Search results
Results From The WOW.Com Content Network
The Children's Oncology Group (COG), a clinical trials group supported by the National Cancer Institute (NCI), is the world's largest organization devoted exclusively to pediatric cancer research. [1] The COG conducts a spectrum of clinical research and translational research trials for infants, children, adolescents, and young adults with cancer.
A cog is a tooth of a gear or cogwheel or the gear itself. Cog, COG, ... Children's Oncology Group, a National Cancer Institute supported clinical trials group;
The Eastern Cooperative Oncology Group (ECOG) began in 1955 as one of the first publicly funded cooperative groups to perform multi-center clinical trials for cancer research. [1] A cooperative group in oncology constitutes a large network of private and public medical institutions developing protocols for cancer treatments. Institutional ...
The Pediatric Oncology Group (POG) was a U.S. and Canadian clinical trial cooperative group created with the mission of studying childhood cancers.It was formed by the merger of the pediatric divisions of two other cooperative groups, the Southwest Oncology Group (SWOG) and the CALGB.
For example, in a colorectal cancer there are usually about 3 to 6 driver mutations and 33 to 66 hitchhiker or passenger mutations. [25] In contrast, in one study of colon tumors compared to adjacent normal-appearing colonic mucosa, 1,734 CpG islands were heavily methylated in tumors whereas these CpG islands were not methylated in the adjacent ...
The most frequent liver cancer, accounting for approximately 75% of all primary liver cancers, is hepatocellular carcinoma (HCC). [15] HCC is a cancer formed by liver cells, known as hepatocytes, that become malignant. In terms of cancer deaths, worldwide HCC is considered the 3rd most common cause of cancer mortalities. [16]
In medicine (oncology and other fields), performance status is an attempt to quantify cancer patients' general well-being and activities of daily life. This measure is used to determine whether they can receive chemotherapy, whether dose adjustment is necessary, and as a measure for the required intensity of palliative care.
Opsoclonus myoclonus syndrome (OMS), also known as opsoclonus-myoclonus-ataxia (OMA), is a rare neurological disorder of unknown cause which appears to be the result of an autoimmune process involving the nervous system.